on Facebook
on Twitter
on YouTube
Document Information
False Hope
Bone Marrow Transplantation for Breast Cancer
Details how the factors that drove clinical use of high-dose chemotherapy with autologous bone marrow transplantation (HDC/ABMT)-patient demand, physician enthusiasm, media reporting, litigation, and administrative mandates-converged to propel the procedure forward despite a lack of proven clinical effectiveness. False Hope also analyzes the failure of the technology assessments and randomized clinical trials that evaluated the procedure and the ramifications of this flawed system on health care today. Sections of the book consider the initial conditions surrounding the emergence of the new breast cancer treatment, the drivers of clinical use, and the struggle for evidence-based medicine. A concluding section addresses the significance of the story for our health care system.
See Also:
Order this document from Oxford University Press
Copies available from booksellers or the publisher. Published by Oxford University Press.
Periodically, RAND Corporation researchers publish with commercial presses. These books are not available from RAND but can be requested directly from the publisher, except in cases where the rights have reverted to RAND and we have republished a new edition.
The RAND Corporation is a nonprofit research organization providing objective analysis and effective solutions that address the challenges facing the public and private sectors around the world. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.
Top
RAND® is a registered trademark. Copyright © 1994-2009 RAND Corporation. Last Modified: March 19, 2008 